Related Experiment Video
Updated: Jun 5, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
[Novel therapy for atherosclerosis and inflammatory vascular disease]
1Department of Laboratory Sciences, School of Health Sciences, Kanazawa University.
Abstract:
How to manage residual atherosclerosis risk after the statin therapy is a major concern in cardiovascular medicine. In addition to life-style modifications, new drugs against atherosclerotic and inflammatory vascular diseases are expected. In current clinical trials, phospholipase A2 inhibitors(darapladib, varespladib), RVX-208, D-4F, CETP inhibitors (anacetrapib, dalcetrapib), succinobucol are investigated. Some has been failed, but others are still promising. On molecular target basis of PAF-AH, CETP, PON, ABC transporters of A1 and G1, SR-BI, HO-1, potential benefits and side effects are discussed.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Atherosclerosis I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease II: Pathophysiology
Peripheral Artery Disease III: Interprofessional Care

